$ 2.11

-0.01(-0.4717%)

05-19 11:59

ORGENESIS INC

Orgenesis, Inc. engages in the cell therapy development and manufacturing for advanced medicinal products. It focuses on developing novel and proprietary cell therapy trans-differentiation technologies for the treatment of diabetes. It operates through the Contract Development and Manufacturing Organization (CDMO), and Cellular Therapy Business (CT) segments. The CDMO segment through MaSTherCell, comprises of companies that provide comprehensive services from cell therapy development through cell therapy manufacturing for and end-to-end solution. The CT segment includes a technology that demonstrates the capacity to induce a shift in the developmental fate of cells from the liver and trans-differentiating them into pancreatic beta cell-like insulin-producing cells. The company was founded on June 5, 2008 by Sarah Ferber and is headquartered in Germantown, MD.
最高:2.30今开:2.19成交量:12.07万股换手:0.49%
最低:2.10昨收:2.12成交额:26.08万振幅:9.43%
52周最高:5.85量比:1.00市盈率(TTM):亏损市净率:1.36
52周最低:2.10委比:-33.33%市盈率(静):亏损市销率:1.40
每股收益:-0.73股息(TTM):--每手股数:1总市值:5237.18万
每股净资产:1.59股息率(TTM):--最小价差:0.01总股本:2482.08万
机构持股:--Beta:--空头回补天数:--货币单位:USD
最新获投
暂无数据
最新动态
暂无数据
五力模型
财务指标
单位:美元
2018-05-31
2018-02-28
2017-11-30
2017-08-31
2017-05-31
流动资产
1,373.80万
856.90万
729.50万
567.40万
611.00万
现金及短期投资
567.70万
422.50万
351.90万
76.20万
65.80万
短期应收账款
342.40万
255.40万
221.00万
227.90万
309.50万
存货
122.90万
88.10万
72.50万
96.50万
90.40万
其他流动资产
340.80万
90.90万
84.10万
166.80万
145.30万
非流动资产
3,329.50万
3,384.20万
3,257.70万
3,174.80万
3,015.70万
厂房及设备净资产
751.70万
561.70万
510.40万
502.50万
480.70万
项目总投资及垫款
113.60万
205.10万
166.00万
48.10万
25.80万
长期应收票据
--
--
--
--
--
无形资产
2,456.00万
2,608.90万
2,573.50万
2,616.30万
2,501.70万
递延所得税资产
--
--
--
--
--
其他资产
8.20万
8.50万
7.80万
7.90万
7.50万
合计总资产
4,703.30万
4,241.10万
3,987.20万
3,742.20万
3,626.70万
流动负债
1,297.20万
1,616.40万
1,691.40万
1,757.10万
1,614.70万
短期债务(含部分LTD)
93.30万
195.80万
315.80万
316.50万
260.50万
应付账款
238.80万
383.80万
391.40万
368.90万
354.10万
应付所得税
--
--
--
--
--
其他流动负债
965.10万
1,036.80万
984.20万
1,071.70万
1,000.10万
非流动负债
213.80万
288.50万
522.90万
860.00万
1,022.20万
长期负债
190.20万
256.70万
453.30万
484.10万
505.60万
拨备风险及费用
5,000.00
6,000.00
6,000.00
5,000.00
5,000.00
递延所得税负债
3.20万
31.20万
69.00万
260.80万
202.70万
其他负债
19.90万
--
--
114.60万
313.40万
合计总负债
1,511.00万
1,904.90万
2,214.30万
2,617.10万
2,636.90万
股东权益合计
2,580.10万
1,947.80万
1,412.30万
1,125.10万
989.80万
非股权储备
--
--
--
--
--
优先股-账面价值
0.00
0.00
0.00
0.00
0.00
普通股权益(合计)
2,580.10万
1,947.80万
1,412.30万
1,125.10万
989.80万
累计少数股东权益
612.20万
388.40万
360.60万
--
--
权益总额
3,192.30万
2,336.20万
1,772.90万
1,125.10万
989.80万
负债与股东权益合计
4,703.30万
4,241.10万
3,987.20万
3,742.20万
3,626.70万
每股账面价值
1.94
1.90
1.43
1.14
1.00
每股账面价值-有形
0.09
-0.64
-1.18
-1.52
-1.52
单位:美元
2018-05-31
2018-02-28
2017-11-30
2017-08-31
2017-05-31
营业总收入
398.70万
263.60万
337.70万
256.20万
229.80万
-营业成本
264.00万
208.00万
233.70万
229.00万
152.50万
毛利
134.70万
55.60万
104.00万
27.20万
77.30万
-销售管理及行政费用
387.10万
411.00万
187.40万
368.40万
309.70万
-其他运营费用
--
--
--
--
--
计息税前利润
-252.40万
-355.40万
-83.40万
-341.20万
-232.40万
+非经营收入(支出)
-65.80万
29.00万
-113.80万
-16.90万
-132.70万
-非经常性支出
-60.60万
-11.70万
44.10万
-234.90万
-294.60万
-利息支出
17.70万
272.60万
24.60万
30.00万
29.80万
税前净利润
-275.30万
-587.30万
-265.90万
-153.20万
-100.30万
-所得税
-27.70万
-39.60万
-180.30万
42.10万
-44.40万
+其他税后调整
0.00
0.00
0.00
0.00
0.00
+联署公司盈利权益
--
--
--
--
--
合并净利润
-247.60万
-547.70万
-85.60万
-195.30万
-55.90万
-少数股东权益开支
13.80万
13.40万
--
--
--
净利润
-261.40万
-561.10万
-85.60万
-195.30万
-55.90万
-优先股股息
--
--
--
--
--
一般可用收入净利润
-261.40万
-561.10万
-85.60万
-195.30万
-55.90万
每股基本收益
-0.20
-0.52
-0.09
-0.24
-0.06
摊薄每股收益
-0.20
-0.52
-0.11
-0.24
-0.06
息税折旧摊销前利润
-187.90万
-291.70万
-11.00万
-274.50万
-170.90万
单位:美元
2017-11-30
2016-11-30
2015-11-30
2014-11-30
净收益
-1,236.70万
-919.40万
-446.10万
-550.41万
+折旧损耗及摊稍
259.80万
292.30万
199.10万
4,551.00
+递延税及投资税减免
-131.00万
-154.60万
-90.00万
--
+其他经营基金
467.00万
168.80万
-129.10万
339.36万
营运资金
-640.90万
-612.90万
-466.10万
-210.60万
+特别项目
--
--
--
--
+营运资金变动
257.60万
234.60万
195.50万
67.67万
经营现金流
-383.30万
-378.30万
-270.60万
-142.92万
资本支出
-97.50万
-142.50万
-98.20万
-4,746.00
收购所得净资产
--
--
30.50万
--
固定资产和业务出售收入
234.90万
--
--
--
投资买卖净额
-242.90万
-11.10万
-25.50万
--
非现金项目
0.00
0.00
0.00
7,255.00
投资现金流
-105.50万
-153.60万
-93.20万
2,509.00
发放现金股利
--
--
--
--
股本变动
529.70万
148.80万
420.30万
97.26万
发行/削减债务净额
71.90万
63.50万
246.30万
176.41万
其他融资基金
--
--
--
--
筹资现金流
601.60万
212.30万
666.60万
273.67万
汇率影响
149.70万
-8.10万
-17.40万
-4.67万
杂项基金
--
--
--
--
现金净流动
262.50万
-327.70万
285.40万
126.32万
自由现金流
-480.80万
-520.80万
-368.80万
-143.40万
公司高管
David Sidransky
Founder of Champions Oncology, Inc. and Israel Biotech Fund, David Sidransky currently is Chairman for Advaxis, Inc., Chairman of Tamir Biotechnology, Inc. and General partner at Israel Biotech Fund. Dr. Sidransky is also Professor at The Johns Hopkins University, Professor at The Johns Hopkins Hospital, Inc., Executive Officer of Biomerk, Inc., Director-Head & Neck Cancer Research Division at The Sidney Kimmel Comprehensive Cancer Center, Director-Head & Neck Cancer Research Division at The Johns Hopkins University School of Medicine and Professor at John Hopkins University and on the board of 6 other companies. In the past Dr. Sidransky held the position of Senior Editor at Clinical Cancer Research. David Sidransky received an undergraduate degree from Brandeis University and a doctorate from Baylor College of Medicine.
Vered Caplan
Vered Caplan is a businessperson who has been the head of 5 different companies and currently occupies the position of Chairman, President & Chief Executive Officer for Orgenesis, Inc. and Chairman at ATVIO Biotech Ltd. and President at MaSTherCell Global, Inc. (both are subsidiaries of Orgenesis, Inc.). Ms. Caplan is also on the board of 6 other companies. In her past career Ms. Caplan was Chief Executive Officer at Kamedis and Chief Executive Officer at Gammacan International, Inc. Vered Caplan received a graduate degree from Tel-Aviv University and an undergraduate degree from Technion-Israel Institute of Technology.
Neil Reithinger
Founder of Eventus Advisory Group LLC, Eventus Consulting PC and Sustinere Holdings, Inc., Neil Reithinger is an entrepreneur and businessperson who has been at the head of 10 different companies and presently is Director, Chief Executive & Financial Officer for Peak Pharmaceuticals, Inc., President, CEO, CFO, Treasurer & Director at Intellisense Solutions, Inc., President, Treasurer & Director at Sustinere Holdings, Inc., President for Eventus Consulting PC, President of Eventus Advisory Group LLC, President at Site 85 Productions, Inc., Chief Financial Officer, Secretary & Treasurer of Orgenesis, Inc. and Chief Financial Officer at ArtVentive Medical Group, Inc. Neil Reithinger is also Member of Arizona Society of Certified Public Accountants and Member of The American Institute of Certified Public Accountants. In the past Mr. Reithinger was Chief Operations & Financial Officer at New Leaf Brands, Inc., President at Strategic Healthcare Systems, Inc., President at Carolco Pictures, Inc., Chief Financial Officer at NaturalShrimp, Inc. and Chief Executive Officer at Nutritional Specialties, Inc. Neil Reithinger received an undergraduate degree from the University of Arizona.
Yaron Adler
Founder of Perion Network Ltd. and Mircod SiP, Yaron Adler is on the board of Inneractive Ltd. and 5 other companies. In the past Mr. Adler occupied the position of President for Perion Network Ltd. and Product Manager at Tecnomatix Technologies Ltd. Mr. Adler received an undergraduate degree from Tel-Aviv University.
Guy Yachin
Guy Yachin is a businessperson who founded Chiasma, Inc. and who has been at the head of 5 different companies. Mr. Yachin is President & Chief Executive Officer at Serpin Pharma, LLC. He is also on the board of Orgenesis, Inc., Thera-P Ltd. and Exxel Pharma, Inc. He previously occupied the position of Chief Executive Officer at Naiot Technological Center Ltd., Chief Executive Officer & General Manager of Therapix Biosciences Ltd., Chief Executive Officer at VESSL Therapeutics Ltd., Chief Executive Officer at Chiasma, Inc. and Senior Consultant at Ofer Technologies Ltd. Mr. Yachin received an undergraduate degree and an MBA from Technion-Israel Institute of Technology.
David Sidransky
Founder of Champions Oncology, Inc. and Israel Biotech Fund, David Sidransky currently is Chairman for Advaxis, Inc., Chairman of Tamir Biotechnology, Inc. and General partner at Israel Biotech Fund. Dr. Sidransky is also Professor at The Johns Hopkins University, Professor at The Johns Hopkins Hospital, Inc., Executive Officer of Biomerk, Inc., Director-Head & Neck Cancer Research Division at The Sidney Kimmel Comprehensive Cancer Center, Director-Head & Neck Cancer Research Division at The Johns Hopkins University School of Medicine and Professor at John Hopkins University and on the board of 6 other companies. In the past Dr. Sidransky held the position of Senior Editor at Clinical Cancer Research. David Sidransky received an undergraduate degree from Brandeis University and a doctorate from Baylor College of Medicine.
Vered Caplan
Vered Caplan is a businessperson who has been the head of 5 different companies and currently occupies the position of Chairman, President & Chief Executive Officer for Orgenesis, Inc. and Chairman at ATVIO Biotech Ltd. and President at MaSTherCell Global, Inc. (both are subsidiaries of Orgenesis, Inc.). Ms. Caplan is also on the board of 6 other companies. In her past career Ms. Caplan was Chief Executive Officer at Kamedis and Chief Executive Officer at Gammacan International, Inc. Vered Caplan received a graduate degree from Tel-Aviv University and an undergraduate degree from Technion-Israel Institute of Technology.
Neil Reithinger
Founder of Eventus Advisory Group LLC, Eventus Consulting PC and Sustinere Holdings, Inc., Neil Reithinger is an entrepreneur and businessperson who has been at the head of 10 different companies and presently is Director, Chief Executive & Financial Officer for Peak Pharmaceuticals, Inc., President, CEO, CFO, Treasurer & Director at Intellisense Solutions, Inc., President, Treasurer & Director at Sustinere Holdings, Inc., President for Eventus Consulting PC, President of Eventus Advisory Group LLC, President at Site 85 Productions, Inc., Chief Financial Officer, Secretary & Treasurer of Orgenesis, Inc. and Chief Financial Officer at ArtVentive Medical Group, Inc. Neil Reithinger is also Member of Arizona Society of Certified Public Accountants and Member of The American Institute of Certified Public Accountants. In the past Mr. Reithinger was Chief Operations & Financial Officer at New Leaf Brands, Inc., President at Strategic Healthcare Systems, Inc., President at Carolco Pictures, Inc., Chief Financial Officer at NaturalShrimp, Inc. and Chief Executive Officer at Nutritional Specialties, Inc. Neil Reithinger received an undergraduate degree from the University of Arizona.
Yaron Adler
Founder of Perion Network Ltd. and Mircod SiP, Yaron Adler is on the board of Inneractive Ltd. and 5 other companies. In the past Mr. Adler occupied the position of President for Perion Network Ltd. and Product Manager at Tecnomatix Technologies Ltd. Mr. Adler received an undergraduate degree from Tel-Aviv University.
Guy Yachin
Guy Yachin is a businessperson who founded Chiasma, Inc. and who has been at the head of 5 different companies. Mr. Yachin is President & Chief Executive Officer at Serpin Pharma, LLC. He is also on the board of Orgenesis, Inc., Thera-P Ltd. and Exxel Pharma, Inc. He previously occupied the position of Chief Executive Officer at Naiot Technological Center Ltd., Chief Executive Officer & General Manager of Therapix Biosciences Ltd., Chief Executive Officer at VESSL Therapeutics Ltd., Chief Executive Officer at Chiasma, Inc. and Senior Consultant at Ofer Technologies Ltd. Mr. Yachin received an undergraduate degree and an MBA from Technion-Israel Institute of Technology.
高管交易状态
暂无数据
持股状况
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Merrill Lynch & Co Inc
200
--
-863
-81.19%
2018-06-30
SevenBridge Financial Group, LLC
250
--
250
--
2018-03-31
Ayalon Mutual Funds Ltd.
650
--
650
--
2018-06-30
Winslow Evans & Crocker Inc
1000
0.01%
1000
--
2018-03-31
Citigroup Inc
1303
0.01%
--
--
2018-06-30
Alumot Mutual Funds Management Ltd
3250
0.02%
--
--
2018-06-30
Panagora Asset Management Inc
4626
0.04%
4626
--
2018-03-31
Morgan Stanley Smith Barney LLC
10125
0.08%
--
--
2018-06-30
Universite Libre de Bruxelles
408792
0.34%
408792
--
2017-11-13
BlackRock Inc
19167
0.14%
19167
--
2018-06-30
Vanguard Group Inc
144817
1.09%
144817
--
2018-06-30
UBS Securities LLC
56
--
56
--
2018-06-30
Royal Bank Of Canada
500
--
500
--
2018-03-31
FMG LLC
1291
0.01%
1291
--
2018-06-30
BlackRock Fund Advisors
18686
0.13%
--
--
2018-08-30
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Vanguard Extended Market Idx Inv
143392
0.98%
--
--
2018-07-31
iShares Micro-Cap
18686
0.11%
--
--
2018-09-12
The Vanguard Total Stock Market Index
1425
0.01%
--
--
2018-07-31
AXA/Lord Abbett Micro Cap K
1291
0.01%
--
--
2018-07-31